Invizius, a biotechnology company developing treatments for patients on dialysis, announced today the appointment of Bernard Canaud to its clinical advisory board.
Canaud brings with him over 40 years of experience as an authority in the field of kidney disease and dialysis, with more than 350 peer-reviewed articles on the subject. In 2009, he was the recipient of the highest French order of merit, the Legion d’Honneur, for his medical achievements. Alongside this new appointment with Invizius, Canaud is currently emeritus professor of Nephrology at the Montpellier University School of Medicine in France.
Richard Boyd, CEO of Invizius, had this to say: “We are delighted and honoured to have Professor Canaud join Invizius at an important time of growth and development for the company. We are now beginning the first-in-human study of H-Guard following recent approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Professor Canaud’s unrivalled experience in the field of nephrology will be instrumental as we look to transform the treatment landscape for dialysis patients.”
When asked to comment, Professor Canaud said: “Invizius’ unique product H-Guard has the potential to reduce the therapeutic burden and save patients’ lives by addressing the inappropriate activation of the complement system. In spite of significant advances in the field of biocompatibility, studies have demonstrated that the persistent activation of the complement system by extracorporeal blood purification or nanomedicine therapy remains potentially harmful in the long and short term for patients exposed to these therapies. By targeting factor H and inhibiting both the alternate complement activation pathway and its amplification loop with H-Guard, we have the ability and potential to make a tremendous difference to patients while mitigating associated risks.”